JP2005508965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508965A5 JP2005508965A5 JP2003536219A JP2003536219A JP2005508965A5 JP 2005508965 A5 JP2005508965 A5 JP 2005508965A5 JP 2003536219 A JP2003536219 A JP 2003536219A JP 2003536219 A JP2003536219 A JP 2003536219A JP 2005508965 A5 JP2005508965 A5 JP 2005508965A5
- Authority
- JP
- Japan
- Prior art keywords
- substrate
- iii
- diagnostic composition
- paramagnetic
- diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000758 substrate Substances 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 15
- 230000005298 paramagnetic effect Effects 0.000 claims 13
- 150000004697 chelate complex Chemical class 0.000 claims 6
- 229910052688 Gadolinium Inorganic materials 0.000 claims 5
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 238000002059 diagnostic imaging Methods 0.000 claims 3
- 150000002500 ions Chemical class 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 238000002595 magnetic resonance imaging Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 claims 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- XMMCPMYPMFYKAZ-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-10-[(3-methoxyphenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound COC1=CC=CC(CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)=C1 XMMCPMYPMFYKAZ-UHFFFAOYSA-N 0.000 claims 1
- BVKGUTLIPHZYCX-UHFFFAOYSA-N 3,3,3-trifluoro-2-hydroxypropanoic acid Chemical group OC(=O)C(O)C(F)(F)F BVKGUTLIPHZYCX-UHFFFAOYSA-N 0.000 claims 1
- LPVYOVZDAGWMDQ-UHFFFAOYSA-N 4-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]methyl]benzoic acid Chemical compound C1CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN1CC1=CC=C(C(O)=O)C=C1 LPVYOVZDAGWMDQ-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 229910052692 Dysprosium Inorganic materials 0.000 claims 1
- 229910052691 Erbium Inorganic materials 0.000 claims 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
- 229910052689 Holmium Inorganic materials 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- 239000002262 Schiff base Substances 0.000 claims 1
- 150000004753 Schiff bases Chemical class 0.000 claims 1
- 229910052771 Terbium Inorganic materials 0.000 claims 1
- 229910052775 Thulium Inorganic materials 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 229910052769 Ytterbium Inorganic materials 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical compound [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 229960003624 creatine Drugs 0.000 claims 1
- 239000006046 creatine Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims 1
- MGVUQZZTJGLWJV-UHFFFAOYSA-N europium(2+) Chemical compound [Eu+2] MGVUQZZTJGLWJV-UHFFFAOYSA-N 0.000 claims 1
- LNBHUCHAFZUEGJ-UHFFFAOYSA-N europium(3+) Chemical compound [Eu+3] LNBHUCHAFZUEGJ-UHFFFAOYSA-N 0.000 claims 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 150000003893 lactate salts Chemical group 0.000 claims 1
- 229910052747 lanthanoid Inorganic materials 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 229940039748 oxalate Drugs 0.000 claims 1
- 150000004032 porphyrins Chemical class 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims 1
- FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 claims 1
- 229910001428 transition metal ion Inorganic materials 0.000 claims 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01124440.7 | 2001-10-11 | ||
| EP01124440A EP1302465A1 (en) | 2001-10-11 | 2001-10-11 | Enhanced substrate imaging by reversible binding to a paramagnetic complex |
| PCT/EP2002/011271 WO2003033479A1 (en) | 2001-10-11 | 2002-10-09 | Enhanced substrate imaging by reversible binding to a paramagnetic complex |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508965A JP2005508965A (ja) | 2005-04-07 |
| JP2005508965A5 true JP2005508965A5 (https=) | 2006-01-05 |
| JP4817600B2 JP4817600B2 (ja) | 2011-11-16 |
Family
ID=8178947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003536219A Expired - Fee Related JP4817600B2 (ja) | 2001-10-11 | 2002-10-09 | 常磁性錯体への可逆性結合による基質画像診断の増強 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7608249B2 (https=) |
| EP (2) | EP1302465A1 (https=) |
| JP (1) | JP4817600B2 (https=) |
| AT (1) | ATE439350T1 (https=) |
| DE (1) | DE60233338D1 (https=) |
| WO (1) | WO2003033479A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1331012A1 (en) | 2002-01-29 | 2003-07-30 | BRACCO IMAGING S.p.A. | Responsive paramagnetic MRI contrast agents |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| EP1716870A1 (en) | 2005-04-29 | 2006-11-02 | Bracco Imaging S.p.A. | MRI contrast agents endowed with concentration independent responsiveness |
| EP2051739A2 (en) * | 2006-08-18 | 2009-04-29 | GE Healthcare AS | Imaging medium comprising lactate and hyperpolarised 13c-pyruvate |
| ES2660173T3 (es) | 2007-01-16 | 2018-03-21 | Ipintl, Llc | Nueva composición para el tratamiento del síndrome metabólico |
| CA2666036C (en) | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
| WO2010056590A2 (en) * | 2008-11-14 | 2010-05-20 | University Of Maryland, Baltimore | Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging |
| EP2473199A1 (en) * | 2009-08-31 | 2012-07-11 | Brain Watch Ltd. | Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
| FR3025317B1 (fr) * | 2014-08-26 | 2022-09-23 | Imabiotech | Methode de caracterisation d'un echantillon par imagerie par spectrometrie de masse |
| US12569170B2 (en) * | 2021-06-10 | 2026-03-10 | Yale University | Paramagnetic sodium NMR macrocyclic-based biosensors, and associated methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885363A (en) * | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US4933441A (en) * | 1987-01-27 | 1990-06-12 | Gibby Wendell A | Contrast enhancing agents for magnetic resonance images |
| US5756065A (en) * | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| US5597548A (en) * | 1990-07-18 | 1997-01-28 | Board Of Regents, The University Of Texas System | 13 C Isotopomer analyses in intact tissue using (13 C) homonuclear decoupling |
| FR2725449B1 (fr) * | 1994-10-05 | 1996-12-27 | Air Liquide | Derives de polyazacycloalcanes, leurs complexes metalliques et produits pharmaceutiques incorporant ces complexes |
| IT1293778B1 (it) * | 1997-07-25 | 1999-03-10 | Bracco Spa | 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli |
| CA2249173C (en) * | 1997-10-06 | 2008-12-16 | Tokyo Gas Co., Ltd. | Diagnostic agent for liver function |
| IT1304501B1 (it) * | 1998-12-23 | 2001-03-19 | Bracco Spa | Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza |
| FR2802928B1 (fr) * | 1999-12-22 | 2003-01-31 | Air Liquide | Polyazacycloalcanes eventuellement greffes sur une matrice solide, complexes organometalliques les incorporant comme ligands. utilisation desdits composes a l'extraction de metaux lourds |
-
2001
- 2001-10-11 EP EP01124440A patent/EP1302465A1/en not_active Withdrawn
-
2002
- 2002-10-09 JP JP2003536219A patent/JP4817600B2/ja not_active Expired - Fee Related
- 2002-10-09 US US10/492,231 patent/US7608249B2/en not_active Expired - Fee Related
- 2002-10-09 EP EP02801319A patent/EP1434768B1/en not_active Expired - Lifetime
- 2002-10-09 WO PCT/EP2002/011271 patent/WO2003033479A1/en not_active Ceased
- 2002-10-09 DE DE60233338T patent/DE60233338D1/de not_active Expired - Lifetime
- 2002-10-09 AT AT02801319T patent/ATE439350T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Le Fur et al. | The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists | |
| Bousquet et al. | Gd-DOTA: characterization of a new paramagnetic complex. | |
| CN108368067B (zh) | 二聚造影剂 | |
| Vitha et al. | Lanthanide (III) complexes of bis (phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy | |
| JP4796643B2 (ja) | 応答性常磁性ｍｒｉ造影剤 | |
| Xie et al. | Iron (III)‐t CDTA derivatives as MRI contrast agents: Increased T1 relaxivities at higher magnetic field strength and pH sensing | |
| HUT74435A (en) | Contrast-materials containing melanin-derivatives | |
| WO1991003200A1 (en) | Hydroxy-aryl metal chelates for diagnostic nmr imaging | |
| Botár et al. | Synthesis and characterization of a stable and inert Mn II-based Zn II responsive MRI probe for molecular imaging of glucose stimulated zinc secretion (GSZS) | |
| JPH08504399A (ja) | ３−，８−置換ジューテロポルフィリン誘導体、これを含用する薬剤及びその製法 | |
| JP2005515842A6 (ja) | 応答性常磁性ｍｒｉ造影剤 | |
| JP2005508965A5 (https=) | ||
| Zhang et al. | Gadolinium complexes of diethylenetriamine-N-oxide pentaacetic acid-bisamide: a new class of highly stable MRI contrast agents with a hydration number of 3 | |
| JP2005515842A5 (https=) | ||
| CN109963838B (zh) | 二聚造影剂 | |
| Tear et al. | An albumin-binding Gd-HPDO3A contrast agent for improved intravascular retention | |
| JP4817600B2 (ja) | 常磁性錯体への可逆性結合による基質画像診断の増強 | |
| JPH09502734A (ja) | 常磁性診断用配合物及びその使用方法 | |
| Li et al. | Mn (II)-monosubstituted polyoxometalates as candidates for contrast agents in magnetic resonance imaging | |
| JPH06509093A (ja) | 新規な磁気共鳴造影用組成物 | |
| Tweedle et al. | Magnetic resonance imaging (MRI) contrast agents | |
| JP7801229B2 (ja) | Ｍｒｉ用造影剤としての鉄錯体およびその塩 | |
| Tweedle | Gadolinium chelates as relaxation agents in magnetic resonance imaging | |
| Pushparaj et al. | Development of novel dinuclear [Gd (III) DO3VA] complexes decorated with isovaleric acid as MRI contrast agents for tumor diagnosis | |
| Nakajima et al. | Current Clinical Issues: Deposition |